Saisheng Pharmaceutical announced that the company recently obtained a “Pharmaceutical Production License” issued by the Beijing Drug Administration, involving changes in production sites for 3 types of monosalicylate tetrahexose ganglioside sodium injections, all adding corresponding production lines at No. 2 Hospital No. 2, Liangshui River Second Street, Beijing Economic and Technological Development Zone, on top of the original production site, with batches of 120,000, 50,000, and 30,000 units respectively. The new variety can only be officially produced after obtaining a drug approval certificate. The change is conducive to improving the company's production capacity, and has no significant impact on the company's performance in the short term.

Saisheng Pharmaceutical announced that the company recently obtained a “Pharmaceutical Production License” issued by the Beijing Drug Administration, involving changes in production sites for 3 types of monosalicylate tetrahexose ganglioside sodium injections, all adding corresponding production lines at No. 2 Hospital No. 2, Liangshui River Second Street, Beijing Economic and Technological Development Zone, on top of the original production site, with batches of 120,000, 50,000, and 30,000 units respectively. The new variety can only be officially produced after obtaining a drug approval certificate. The change is conducive to improving the company's production capacity, and has no significant impact on the company's performance in the short term.